The immune function evaluation also revealed that glioma patients in the high-risk group had significantly higher immunological scores than those in the low-risk group in a number of immune function modulations, such as Check point, Type I/II IFN Response, and Inflammation promoting (Fig. 7D). The gene discussed is IFNA1; the disease is central nervous system cancer.